Yilmaz Betul, Zuckerman Warren A, Lee Teresa M, Beddows Kimberly D, Gilmore Lisa A, Singh Rakesh K, Richmond Marc E, Chen Jonathan M, Addonizio Linda J
Division of Cardiology, Department of Pediatrics, Morgan Stanley Children's Hospital, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Pediatr Transplant. 2013 Aug;17(5):E113-6. doi: 10.1111/petr.12096. Epub 2013 May 26.
Orthotopic heart transplantation remains the definitive treatment of choice for patients with end-stage heart failure; however, elevated PVRI is a reported risk factor for mortality after heart transplant and, when severely elevated, is considered an absolute contraindication. Use of a ventricular assist device has been proposed as one treatment for reducing pulmonary vascular resistance index in potential heart transplant candidates refractory to medical vasodilator therapies. We report on a teenage patient with dilated cardiomyopathy and severely elevated PVRI, unresponsive to pulmonary vasodilator therapy, who underwent left ventricular assist device implantation to safely allow for aggressive pulmonary vasodilator therapy and to decrease PVRI. The resulting dramatic improvement in PVRI in a relatively short period of time allowed for successful heart transplantation, avoiding the need for heart-lung transplant.
原位心脏移植仍然是终末期心力衰竭患者的首选确定性治疗方法;然而,据报道,肺血管阻力指数(PVRI)升高是心脏移植后死亡的一个危险因素,当严重升高时,被视为绝对禁忌证。对于潜在的心脏移植候选人,若对药物性血管扩张疗法无效,使用心室辅助装置已被提议作为一种降低肺血管阻力指数的治疗方法。我们报告了一名患有扩张型心肌病且PVRI严重升高的青少年患者,该患者对肺血管扩张疗法无反应,接受了左心室辅助装置植入术,以便安全地进行积极的肺血管扩张治疗并降低PVRI。在相对较短的时间内,PVRI得到显著改善,从而得以成功进行心脏移植,避免了心肺移植的需要。